MX348025B - Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica. - Google Patents

Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.

Info

Publication number
MX348025B
MX348025B MX2013004879A MX2013004879A MX348025B MX 348025 B MX348025 B MX 348025B MX 2013004879 A MX2013004879 A MX 2013004879A MX 2013004879 A MX2013004879 A MX 2013004879A MX 348025 B MX348025 B MX 348025B
Authority
MX
Mexico
Prior art keywords
macular degeneration
related macular
advanced age
polygenic score
predicting progression
Prior art date
Application number
MX2013004879A
Other languages
English (en)
Other versions
MX2013004879A (es
Inventor
w behrens Timothy
r graham Robert
Original Assignee
Genentech Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc * filed Critical Genentech Inc *
Publication of MX2013004879A publication Critical patent/MX2013004879A/es
Publication of MX348025B publication Critical patent/MX348025B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

La presente invención se refiere a un método para identificar un sujeto o paciente humano diagnosticado con degeneración macular relacionada con la edad (AMD) en etapa temprana o intermedia como estando en riesgo de desarrollar AMD avanzada, caracterizado porque comprende: (a) determinar la frecuencia alélica en por lo menos 10,000 ubicaciones independientes seleccionada a partir de polimorfismos de un solo nucleótido o de nucleótidos individuales expuestos en la Tabla S1, (b) calcular la puntuación poligénica para el paciente multiplicando el log (logaritmo) de la razón Od por cada uno de los polimorfismos de un solo nucleótido por el número de alelos de referencia trasportados por el paciente humano y dividiendo la suma resultante por el número de polimorfismos de un solo nucleótido probados, (c) identificar el paciente humano que está en riesgo de desarrollar AMD avanzada, cuando la puntuación poligénica es mayor de 0.0001, y (d) seleccionar al sujeto humano identificado que está en riesgo de desarrollar AMD avanzada para tratamiento de la AMD.
MX2013004879A 2010-11-01 2011-11-01 Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica. MX348025B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40903910P 2010-11-01 2010-11-01
US201161573602P 2011-09-09 2011-09-09
PCT/US2011/058829 WO2012061421A1 (en) 2010-11-01 2011-11-01 Predicting progression to advanced age-related macular degeneration using a polygenic score

Publications (2)

Publication Number Publication Date
MX2013004879A MX2013004879A (es) 2013-07-02
MX348025B true MX348025B (es) 2017-05-24

Family

ID=45002128

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004879A MX348025B (es) 2010-11-01 2011-11-01 Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.

Country Status (22)

Country Link
US (3) US20120107315A1 (es)
EP (2) EP3170905A1 (es)
JP (4) JP2013544512A (es)
KR (1) KR20130130732A (es)
CN (1) CN103201393B (es)
AR (1) AR083677A1 (es)
AU (2) AU2011323487B2 (es)
BR (1) BR112013010769A2 (es)
CA (1) CA2816805A1 (es)
DK (1) DK2635704T3 (es)
ES (1) ES2628806T3 (es)
HU (1) HUE032938T2 (es)
IL (1) IL226063A0 (es)
MX (1) MX348025B (es)
NZ (1) NZ610067A (es)
PL (1) PL2635704T3 (es)
RU (2) RU2593954C2 (es)
SG (2) SG10201605904PA (es)
SI (1) SI2635704T1 (es)
TW (1) TW201250003A (es)
WO (1) WO2012061421A1 (es)
ZA (1) ZA201303001B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2883245A1 (en) * 2012-09-06 2014-03-13 Ancestry.Com Dna, Llc Using haplotypes to infer ancestral origins for recently admixed individuals
WO2015017536A1 (en) * 2013-07-31 2015-02-05 The Board Of Trustees Of The Leland Stanford Junior University Method and system for evaluating progression of age-related macular degeneration
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
RU2559090C1 (ru) * 2014-08-27 2015-08-10 Александр Владимирович Кулик Способ прогнозирования персонифицированного риска развития макулодистрофии
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
CN106086222A (zh) * 2016-08-24 2016-11-09 厦门美因生物科技有限公司 基于qPCR分型技术的运动基因检测评估方法及系统
US20190267112A1 (en) * 2016-10-30 2019-08-29 Taliaz Ltd. Method and system for predicting response of a subject to antidepressant treatment
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
EP3622660B1 (en) * 2017-05-12 2023-08-30 Massachusetts Institute of Technology Systems and methods for crowdsourcing, analyzing, and/or matching personal data
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CN109585017B (zh) * 2019-01-31 2023-12-12 上海宝藤生物医药科技股份有限公司 一种年龄相关性黄斑变性的风险预测算法模型和装置
KR20220006010A (ko) * 2020-07-07 2022-01-14 주식회사 카나프테라퓨틱스 보체 경로 억제제 및 혈관신생 억제제를 포함하는 융합단백질 및 이의 용도
RU2758662C1 (ru) * 2021-03-19 2021-11-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) Способ определения показаний к антиангиогенной терапии при подозрении на влажную форму возрастной макулярной дегенерации

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US6379929B1 (en) * 1996-11-20 2002-04-30 The Regents Of The University Of Michigan Chip-based isothermal amplification devices and methods
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
WO2002072780A2 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
RU2186392C1 (ru) * 2001-04-26 2002-07-27 Должич Галина Ивановна Способ диагностики сенильной макулярной дистрофии сетчатки
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
CN1950826A (zh) * 2004-03-05 2007-04-18 佩勒根科学有限公司 遗传分析的方法
US7527970B2 (en) 2004-10-15 2009-05-05 The United States Of America As Represented By The Department Of Health And Human Services Method of identifying active chromatin domains
JP5068175B2 (ja) * 2005-01-04 2012-11-07 日立化成工業株式会社 プライマー生成ローリングサークル型増幅
NZ595305A (en) * 2005-02-14 2013-06-28 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
CN101495651A (zh) * 2005-06-08 2009-07-29 匹兹堡大学 染色体10q26上的年龄-相关黄斑病变（ARM）易感基因
WO2007056227A2 (en) * 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
US20080146501A1 (en) * 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
CA2705500A1 (en) * 2007-05-11 2008-11-20 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
US20090203001A1 (en) * 2007-08-24 2009-08-13 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating macular degeneration
CA2721503A1 (en) * 2008-04-18 2009-12-03 Massachusetts General Hospital Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
AT506998B1 (de) * 2008-06-30 2010-03-15 Fronius Int Gmbh Kontaktrohr für einen schweissbrenner
WO2010075519A2 (en) * 2008-12-23 2010-07-01 Massachusetts Eye & Ear Infirmary Allelic variants associated with advanced age-related macular degeneration
WO2010085542A2 (en) * 2009-01-23 2010-07-29 Novartis Ag Biomarkers related to age-related macular degeneration (amd)

Also Published As

Publication number Publication date
SG190078A1 (en) 2013-06-28
ZA201303001B (en) 2014-10-29
SG10201605904PA (en) 2016-09-29
EP2635704B1 (en) 2017-04-19
RU2013125230A (ru) 2014-12-10
JP2018068285A (ja) 2018-05-10
ES2628806T3 (es) 2017-08-04
CN103201393A (zh) 2013-07-10
WO2012061421A1 (en) 2012-05-10
JP2019216732A (ja) 2019-12-26
US20140286947A1 (en) 2014-09-25
PL2635704T3 (pl) 2017-09-29
NZ610067A (en) 2015-05-29
EP3170905A1 (en) 2017-05-24
EP2635704A1 (en) 2013-09-11
AR083677A1 (es) 2013-03-13
RU2016127684A3 (es) 2018-12-06
AU2011323487A1 (en) 2013-06-13
KR20130130732A (ko) 2013-12-02
AU2016256692A1 (en) 2016-11-24
CA2816805A1 (en) 2012-05-10
MX2013004879A (es) 2013-07-02
SI2635704T1 (sl) 2017-07-31
DK2635704T3 (en) 2017-06-19
IL226063A0 (en) 2013-06-27
BR112013010769A2 (pt) 2019-09-24
RU2016127684A (ru) 2018-12-06
TW201250003A (en) 2012-12-16
JP2016154538A (ja) 2016-09-01
US20120107315A1 (en) 2012-05-03
AU2011323487B2 (en) 2016-08-11
RU2593954C2 (ru) 2016-08-10
CN103201393B (zh) 2019-01-18
HUE032938T2 (hu) 2017-11-28
JP2013544512A (ja) 2013-12-19
US20180163262A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
MX2013004879A (es) Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
MX2007009565A (es) Metodos y reactivos para tratamiento y diagnostico de degeneracion macular relacionada con la edad.
WO2010001419A3 (en) Copy number variations predictive of risk of schizophrenia
GB201103062D0 (en) Method
EP2639328A4 (en) High-strength spring steel, method for producing high-strength spring, and high-strength spring
EP2342335A4 (en) NEW GROUP OF GENES
EP2855708A4 (en) METHOD OF DESIGNING PRIMERS, MONONUCLEOTIDE POLYMORPHISM DETECTION METHOD (SNP), SNP DISTINCTION METHOD, AND RELATED PRIMERS, DETECTABLE OLIGONUCLEOTIDES, AND KITS
EP2671964A4 (en) High-strength cold-rolled steel sheet having excellent processability and high yield ratio, and method for producing same
MX344246B (es) Procedimiento para la preparacion de cloruros de acido 5-fluoro-1-alquil-3-fluoroalquil-1h-pirazol-4-carboxilico.
WO2012166626A8 (en) Reagents and methods for treating dental disease
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
HK1162056A1 (en) Identification method for genetic disease-related gene
TN2013000385A1 (en) Processes for the manufacture of macrocyclic depsipeptides and new intermediates
MX349801B (es) Sustratos de enzimas de ácido nucleico.
SI2417267T1 (sl) Postopek zdravljenja na podlagi polimorfizmov gena KCNQ1
PH12015501176B1 (en) Primers, snp markers and method for genotyping mycobacterium tuberculosis
WO2011044458A8 (en) Compositions and methods for diagnosing genome related diseases and disorders
WO2010127290A3 (en) Improved isoprene hydrocarbon production using genetically engineered cyanobacteria
MY158910A (en) Surface modified silicic acid semi-gels
ZA201107977B (en) Prope set identification of nucleotide mutation, and method for identification of nucleotide mutation
HK1184823A1 (en) Novel soil microorganism, novel oxidoreductase separated from the soil microorganism, gene encoding the oxidoreductase, and method for producing aglycones using the microorganism, the oxidoreductase and the gene
WO2011130426A3 (en) Compositions and methods for treatment of melanoma
HK1198656A1 (en) Compositions, methods, and kits for nucleic acid hybridization
WO2012154271A3 (en) Method and cells for identifying rig-i pathway regulators

Legal Events

Date Code Title Description
FG Grant or registration